Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability

Current HIV Research

Volumn 6, Issue 2, 2008, Pages 130-137

  Figueiredo, Anna ^a,d   Zelina, Shannon ^b   Sluis Cremer, Nicolas ^b   Tachedjian, Gilda ^a,c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MONASH UNIVERSITY   (Australia)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Dimerization; Efavirenz; Nonnucleoside reverse transcriptase inhibitors; Polymerase; Resistance; Ribonuclease H; Yeast two hybrid

Indexed keywords

DNA POLYMERASE; EFAVIRENZ; HETERODIMER; PROTEIN SUBUNIT; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; DNA DIRECTED DNA POLYMERASE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; UNCLASSIFIED DRUG;

COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME STABILITY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; RESIDUE ANALYSIS; REVIEW; TWO HYBRID SYSTEM; VIRUS RECOMBINANT; VIRUS RESISTANCE; WILD TYPE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CHEMISTRY; DIMERIZATION; GENETICS; KINETICS; METABOLISM; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; BINDING SITES; DIMERIZATION; DNA-DIRECTED DNA POLYMERASE; ENZYME STABILITY; HIV REVERSE TRANSCRIPTASE; KINETICS; MUTAGENESIS, SITE-DIRECTED; RIBONUCLEASE H; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 41249088246     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783885065     Document Type: Review

References (46)

1. Jacobo-Molina A, Ding J, Nanni RG, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-6324.
2. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995; 2: 303-308.
3. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-993.
4. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″ -dioxo-1″,2″ - oxathiole-5″,3′-2′, 5′-bis-O-(tert-butyldimethylsily1)-beta-D-ribofuranosyl]]]-3- ethylthymine. Biochemistry 2000; 39: 1427-1433.
5. Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 2002; 62: 398-405.
6. Srivastava S, Sluis-Crenter N, Tachedjian G. Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target. Curr Pharm Des 2006; 12: 1879-1894.
7. Divita G, Restle T, Goody RS, Chermann JC, Baillon JG. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994; 269: 13080-13083.
8. Pandey PK, Kaushik N, Singh K, et al. Insertion of a small peptide of six amino acids into the beta7-beta8 loop the p51 subunit of HIV-1 reverse transcriptase perturbs heterodimer and affects its activities. BMC Biochem 2002; 3: 18.
9. Tachedjian G, Aronson HE, de los Santos M, Seehra J, McCoy JM, Goff SP. Role of residues in the tryptophan repeat motif for HIV-1 reverse, transcriptase dimerization. J Mol Biol 2003; 326: 381-396.
10. Tachedjian G, Radzio J, Sluis-Cremer N. Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins 2005; 60: 5-13.
11. Balzarini J, Auwerx J, Rodriguez-Barrios F, et al. The amino acid Asn136 in HIV-1 reverse trariscriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. Mol Pharmacol 2005; 68: 49-60.
12. Auwerx J, Van Nieuwenhove J, Rodriguez-Barrios F, et al. The N 137 and P 140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. FEBS Lett 2005; 579: 2294-2300.
13. Sluis-Cremer N, Harnamouch N, San Felix A, Velazquez S, Balzarini J, Camarasa MJ. Structure-activity relationships of [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3′-spiro-5′ ′-(4′ ′-amino-1′, ′,2′ ′-oxathiole-2′ ′,2′ ′-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. J Med Chem 2006; 49: 4834-4841.
14. Tachedjian G, Orlova M, Sarafianos SG, Arnold E_Goff SP. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 2001; 98: 7188-7193.
15. Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett 2005; 579: 379-384.
16. Venezia CF, Howard KJ, Ignatov ME, Holladay LA, Barkley MD. Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase. Biochemistry 2006; 45: 2779-2789.
17. Xia Q, Radzio J, Anderson KS, Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci 2007; 16: 1728-1737.
18. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284-291.
19. Tachedjian G, Aronson HE, Goff SP. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc Nat Acad Sci USA 2000; 97: 6334-6339.
20. Nissley DV, Radzio J, Ambrose Z, et al. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem J 2007; 404:151-157.
21. Maier G, Dietrich U, Panhans B, et al. Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli - two tags tie it up. Eur J Biochem 1999; 261: 10-18.
22. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type I mutations selected in patients failing efavirenz combination therapy. Antimicrob, Agents Chemother 2000; 44: 2475-2484.
23. Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42: 1340-1345.
24. Huang W, Gamamik A, Limoli K, Petropoulos CJ, Whitcomb JM. Amino acid substitutions at Position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003; 77: 1512-1523.
25. Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 1994; 200: 696-701.
26. Pelemans H, Esnouf R, Dunkler A, et al. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol 1997; 71: 8195-8203.
27. Harrigan PR, Salim M, Stammers DK, et al. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with normucleoside reverse transcriptase inhibitor resistance. J Virol 2002; 76: 6836-6840.
28. Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage leading to diminished zidovudine excision. Mol Pharmacol 2007; in press.
29. Wohrl BM, Krebs R, Thrall SH, Le Grice SF, Scheidig AJ, Goody RS, Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66. Implications for DNA synthesis and dimerization. J Biol Chem 1997; 272: 17581-17587.
30. Auwerx J, Rodriguez-Barrios F, Ceccherini-Silberstein F, et al. The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A. Mol Pharmacol 2005; 68: 652-659.
31. Boyer PL, Gao HQ, Hughes SH. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 1998, 42: 447-452.
32. Wang J, Dykes C, Domaoal RA, Koval CE, Bambara RA, Demeter LM. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 2006; 348: 462-474.
33. Fan N, Rank KB, Slade DE, et al. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry 1996; 35: 9737-9745.
34. Kroeger Smith MB, Michejda CJ, Hughes SH, et al. Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action. Protein Eng 1997;10: 1379-1383.
35. Das K, Ding J, Hsiou Y, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181 Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996; 264: 1085-1100.
36. Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, Bambara RA. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. J Biol Chem 1997; 272: 11157-11164.
37. Palaniappan C, Fay PJ, Bambara RA. Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 1995; 270: 4861-4869.
38. Hang JQ, Li Y, Yang Y, Cammack N, Mirzadegan T, Klumpp K. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun 2007; 352: 341-350.
39. Gerondelis P, Archer RH, Palaniappan C, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol 1999; 73: 5803-5813.
40. Archer RH, Dykes C, Gerondelis P, et al. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000; 74: 8390-8401.
41. Gao HQ, Boyer PL, Arnold E, Hughes SH. Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase. J Mol Biol 1998; 277: 559-572
42. Shaw-Reid CA, Feuston B, Munshi V, et al. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 2005; 44: 1595-1606.
43. Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002; 49: 61-70.
44. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004; 2: 323-332.
45. Shen L, Shen J, Luo X, et al. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys J 3003; 84: 3547-3563.
46. Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog 2006; 2: e119.